Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024
Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid overload solutions, has announced it will release its third quarter 2024 financial results on November 11, 2024. The company will host a conference call and webcast at 9:00 AM ET to discuss financial results and provide a business update. Investors can access the webcast through the company's investor relations website or join via telephone using the provided dial-in numbers.
Nuwellis (Nasdaq: NUWE), un'azienda di tecnologia medica specializzata in soluzioni per il sovraccarico di fluidi, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 l'11 novembre 2024. L'azienda ospiterà una conferenza telefonica e una webcast alle 9:00 ET per discutere dei risultati finanziari e fornire un aggiornamento sull'andamento dell'azienda. Gli investitori possono accedere alla webcast tramite il sito web delle relazioni con gli investitori dell'azienda o partecipare telefonicamente utilizzando i numeri di accesso forniti.
Nuwellis (Nasdaq: NUWE), una empresa de tecnología médica especializada en soluciones para la sobrecarga de líquidos, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el 11 de noviembre de 2024. La empresa organizará una llamada de conferencia y una transmisión en línea a las 9:00 AM ET para discutir los resultados financieros y proporcionar una actualización empresarial. Los inversores pueden acceder a la transmisión a través del sitio web de relaciones con inversores de la empresa o unirse por teléfono utilizando los números de marcado proporcionados.
Nuwellis (Nasdaq: NUWE), 액체 과부하 솔루션을 전문으로 하는 의료 기술 회사로, 2024년 3분기 재무 결과를 2024년 11월 11일 발표할 것이라고 발표했습니다. 회사는 9:00 AM ET에 재무 결과를 논의하고 비즈니스 업데이트를 제공하기 위한 컨퍼런스 콜 및 웹캐스트를 개최합니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접속하거나 제공된 전화 접속 번호를 사용하여 전화로 참여할 수 있습니다.
Nuwellis (Nasdaq: NUWE), une entreprise de technologie médicale spécialisée dans les solutions de surcharge liquidienne, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le 11 novembre 2024. L'entreprise organisera un appel conférence et un webcast à 9h00 ET pour discuter des résultats financiers et fournir une mise à jour commerciale. Les investisseurs peuvent accéder au webcast via le site internet des relations avec les investisseurs de l'entreprise ou se joindre par téléphone en utilisant les numéros de composition fournis.
Nuwellis (Nasdaq: NUWE), ein Medizintechnikunternehmen, das sich auf Lösungen gegen Flüssigkeitsüberlastung spezialisiert hat, hat angekündigt, dass es seine finanziellen Ergebnisse für das dritte Quartal 2024 am 11. November 2024 veröffentlichen wird. Das Unternehmen wird um 9:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen Ergebnisse zu besprechen und ein Geschäfts-Update zu geben. Investoren können über die Website der Investor Relations des Unternehmens auf den Webcast zugreifen oder sich per Telefon über die angegebenen Einwahlnummern einwählen.
- None.
- None.
MINNEAPOLIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the third quarter of 2024 on Monday, November 11, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-445-7795 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ3. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group LLC
ir@nuwellis.com
FAQ
When will Nuwellis (NUWE) release Q3 2024 earnings?
What time is Nuwellis (NUWE) Q3 2024 earnings call?
How can I access Nuwellis (NUWE) Q3 2024 earnings call?
